Product Description
Azasetron (Serotone) is a potent and selective 5-HT3 receptor antagonist, and classified as benzamide derivative. It has a different chemical structure from indole-type 5-HT3 receptor antagonists such as granisetron, ondansetron, ramosetron and tropisetron. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/10396331/)
Mechanisms of Action: 5-HT3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sensorion
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ChiCTR2500095295 | N/A |
Recruiting |
Depressive Disorder|Pain, Postoperative |
2027-11-30 |
|||
| ChiCTR2300078516 | N/A |
Not yet recruiting |
Anesthesia Related |
2026-08-31 |
2023-12-12 |
Treatments |
|
| ChiCTR2300076786 | N/A |
Not yet recruiting |
Unknown |
2024-10-20 |
2023-10-19 |
Treatments |
|
| ChiCTR2200060139 | N/A |
Not yet recruiting |
Chronic Pain|Pain, Postoperative |
2023-12-31 |
2023-03-12 |
Treatments |
|
| ChiCTR2000039603 | N/A |
Recruiting |
Unknown |
2021-12-01 |
|||
| ChiCTR2100049246 | N/A |
Not yet recruiting |
Other |
2021-12-31 |
|||
| ChiCTR-IPR-15007303 | N/A |
Recruiting |
Unknown |
2016-06-30 |